Zepbound vs Mounjaro: Same Drug, Different Uses

Let's be completely clear: Zepbound and Mounjaro contain the identical molecule — tirzepatide — made by the same company (Eli Lilly) at the same facilities. The injection pens are the same. The doses are the same. The side effects are the same. If you held both pens side by side, the only difference would be the label and the box color.

Why two names? The FDA requires separate approvals for different indications. Lilly ran separate clinical trial programs:

• SURPASS trials: Tested tirzepatide for type 2 diabetes → approved as Mounjaro (May 2022)
• SURMOUNT trials: Tested tirzepatide for weight management → approved as Zepbound (November 2023)

This is standard pharmaceutical practice. Semaglutide did the same thing: Ozempic (diabetes) and Wegovy (weight loss) are the same molecule.

Zepbound is FDA-approved for:

• Chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
• Used as an adjunct to diet and increased physical activity

Mounjaro is FDA-approved for:

• Type 2 diabetes mellitus, as an adjunct to diet and exercise
• Not approved for type 1 diabetes

If you have both diabetes and obesity: Your doctor could technically prescribe either one. In practice, many physicians prescribe Mounjaro (the diabetes indication) because insurance coverage is often better for diabetes medications.

Off-label use: Some doctors prescribe Mounjaro off-label for weight loss in patients without diabetes, because diabetes drug coverage is more widespread. This is legal but may not be covered by all insurance plans, and some pharmacists may flag it.

This is the only difference that actually affects your life.

Mounjaro (diabetes indication):

• Covered by most commercial insurance plans with diabetes coverage
• Medicare Part D covers diabetes medications (subject to formulary)
• Prior authorization usually required (but approvals are common for diabetes)
• Copay savings card available: as low as $25/mo

Zepbound (weight management indication):

• Coverage varies widely — many commercial plans exclude weight loss drugs
• Medicare historically did not cover anti-obesity medications (changing in 2026 with new provisions)
• Prior authorization required and often denied
• Copay savings card available: as low as $25/mo
• LillyDirect self-pay: $499/mo (if not using insurance)

The practical impact: If you have type 2 diabetes, your insurance is far more likely to cover tirzepatide as Mounjaro than as Zepbound. If you only have obesity without diabetes, you may need to go through Zepbound and face coverage challenges.

Since they're the same drug, switching is seamless:

• No titration adjustment needed — continue the same dose
• No washout period
• No change in side effects to expect
• Simply fill the other brand at your pharmacy

When might you switch?

• Mounjaro → Zepbound: If your diabetes is well-controlled and your primary goal shifts to weight management, your doctor may rewrite the prescription as Zepbound. This is uncommon since Mounjaro typically has better coverage.
• Zepbound → Mounjaro: If you develop type 2 diabetes while on Zepbound, switching the prescription to Mounjaro may improve insurance coverage. The drug itself doesn't change.

Important: Talk to your doctor and pharmacist before switching labels. Insurance formularies and prior authorization requirements differ between the two brand names, even though the drug is identical.